Hong Kong · Delayed Price · Currency is HKD 3D Medicines Company Description
3D Medicines Inc., a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products in the People’s Republic of China.
The company offers Envafolimab, a PD-L1 antibody in the form of subcutaneous injection for the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient(dMMR) advanced solid tumors.
It is also developing Envafolimab, which is in Phase III clinical trials for advanced BTC and NSCLC, and TMB-H advanced cancer; and in Phase II clinical trials G/GEJ, EC, HCC, CRC, NSCLC, microsatellite stable CRC, and dMMR advanced sold tumors.
In addition, it develops 3D189 for multi-indication tumor that has completed Phase I and is in phase III clinical trial for the treatment of acute myeloid leukemia (AML); 3D229 (GAS6/AXL) for the treatment of acute myeloid leukemia (AML), kidney cancer, pancreatic cancer, breast cancer, lung cancer, ovarian cancer, and prostate cancer and has completed phase I clinical trial; 3D1001 for the treatment of post-surgical dental pain/cancer pain which is in phase II trial; 3D1002 for cancer pain/osteoarthritis and is in phase II trial; and 3D185, which is in phase I clinical trial for the treatment of locally advanced or metastatic solid tumors.
Further, the company is developing 3D011 for advanced malignant solid tumor which is in Phase I clinical trial; 3D1015 for the treatment of metastatic castration-resistant prostate cancer which is in Phase I clinical trial; 3D197 for multi-indication tumor immunotherapy that is in Phase I clinical trial; 3D125; 3D124; and 3D197, 3D057, 3D229, 3D059, and 3D062 for multiple indications tumors which are in preclinical trial.
3D Medcines Inc. was founded in 2014 and is headquartered in Qingdao, China.
| Country | Cayman Islands |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 162 |
| CEO | Zhaolong Gong |
Contact Details
Address: No. 3 and No. 5, Laiyang Road Qingdao, 266000 China | |
| Phone | 86 21 5221 0800 |
| Website | 3d-medicines.com |
Stock Details
| Ticker Symbol | 1244 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG8872R1011 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Zhaolong Gong M.D., Ph.D. | Key Founder, Chief Executive Officer and Executive Chairman |
| Xiaohao Lu CPA | Chief Financial Officer |
| Ming Zhu | Vice President and Head of Operations |
| Dr. Shen Xiao | Chief Strategy Officer and Chief Medical Officer |
| Fang Xia | Head of Board Affairs and Capital Markets Department, Vice President and Joint Company Secretary |
| Gan Ding | Chief Commercial Officer |
| Ching Yi Li | Joint Company Secretary |